Cassava Sciences Inc (OQ:SAVA)

Business Focus: Bio Therapeutic Drugs

Apr 15, 2024 09:20 am ET

Redemption Date Announced for Warrants

Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the...

Apr 05, 2024 06:00 am ET

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Apr 02, 2024 10:20 am ET

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities...

Apr 01, 2024 03:40 pm ET

Cassava Sciences, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 2, 2024 deadline.

The Portnoy Law Firm advises Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) investors that a lawsuit was filed on behalf of investors that purchased Cassava securities between August 18, 2022 and October 12, 2023, inclusive (the...

Apr 01, 2024 06:00 am ET

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 31, 2024 03:07 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA). The class action, filed in the United States District Court for the Northern District of Illinois, and...

Mar 31, 2024 12:13 pm ET

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action – SAVA

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and October 12, 2023, both dates inclusive (the “Class Period”) of the important April 2,...

Mar 31, 2024 07:00 am ET

APRIL 2 FINAL DEADLINE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 31, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its...

Mar 30, 2024 07:00 am ET

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 29, 2024 10:40 am ET

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

NEW YORK, March 29, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Mar 29, 2024 07:00 am ET

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 28, 2024 11:01 am ET

Holzer & Holzer, LLC Reminds Shareholders of April 2, 2024 Lead Plaintiff Deadline in Cassava Sciences, Inc. (SAVA) Class Action – Nationally Ranked Investors’ Rights Firm Encourages Investors With Si

A shareholder class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material adverse...

Mar 28, 2024 10:15 am ET

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead...

Mar 28, 2024 07:00 am ET

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 27, 2024 04:59 pm ET

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA

NEW YORK, March 27, 2024 /PRNewswire/ --

Mar 27, 2024 02:05 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

NEW YORK, March 27, 2024 /PRNewswire/ -- (PRNEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). The class action, filed in the United States District Court for the Northern District of Illinois, and docketed under 24 -cv- 00977, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between August 18, 2022 and October 12, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by D

Mar 27, 2024 03:30 am ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 26, 2024 07:00 am ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 25, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cassava Sciences, Inc. (NASDAQ: SAVA), New York Community Bancorp, Inc. (NYSE:...

Mar 25, 2024 09:13 am ET

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease. A...

Mar 25, 2024 07:00 am ET

APRIL 2 FINAL DEADLINE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 24, 2024 03:45 pm ET

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action – SAVA

Mar 24, 2024 07:00 am ET

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 24, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Mar 23, 2024 01:54 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Mar 23, 2024 07:00 am ET

APRIL 2 DEADLINE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 22, 2024 07:00 am ET

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 21, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Mar 21, 2024 11:45 am ET

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

NEW YORK, March 21, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Mar 21, 2024 07:00 am ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 19, 2024 10:45 am ET

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Mar 17, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Mar 17, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Mar 16, 2024 02:00 pm ET

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Mar 15, 2024 03:26 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Mar 14, 2024 12:00 pm ET

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Mar 12, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of GrafTech International Ltd. (NYSE: EAF), Maplebear, Inc. d/b/a Instacart...

Mar 12, 2024 04:15 pm ET

ROSEN, A LEADING NATIONAL FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Mar 10, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Mar 08, 2024 11:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Mar 07, 2024 10:45 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Mar 07, 2024 10:15 am ET

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Mar 05, 2024 07:10 pm ET

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Mar 04, 2024 09:15 am ET

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD...

Mar 03, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Mar 01, 2024 10:15 am ET

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Feb 29, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of The Boeing Company (NYSE: BA), Brooge Energy Limited (NASDAQ: BROG), Cassava...

Feb 28, 2024 10:53 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Feb 28, 2024 09:14 am ET

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates. “I see Alzheimer’s disease as...

Feb 27, 2024 05:17 pm ET

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Feb 25, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Feb 25, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Feb 24, 2024 09:00 am ET

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

NEW YORK, Feb. 24, 2024 /PRNewswire/ --

Feb 23, 2024 12:36 pm ET

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Feb 23, 2024 11:30 am ET

CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss

Feb 21, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Feb 21, 2024 09:45 am ET

CASSAVA SCIENCES INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences To Contact Him Directly To Discuss Th

If you suffered losses exceeding $100,000 investing in Cassava Sciences stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SAVA.

Feb 20, 2024 10:50 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Feb 18, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Feb 17, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Feb 17, 2024 12:00 pm ET

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Feb 16, 2024 05:45 pm ET

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

NEW YORK, Feb. 16, 2024 /PRNewswire/ --

Feb 16, 2024 09:15 am ET

CASSAVA SCIENCES SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences To Contact Him Directly

Feb 15, 2024 12:30 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). The class action, filed in the United States District Court for the Northern District of Illinois, and docketed under 24 -cv- 00977, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between August 18, 2022 and October 12, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' vio

Feb 15, 2024 09:45 am ET

CASSAVA SCIENCES INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences T

Feb 13, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Feb 11, 2024 09:05 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Feb 11, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Feb 11, 2024 04:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Feb 11, 2024 03:00 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, Feb. 11, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) and certain of its officers.

Feb 09, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brooge, and Cassava and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Brooge Energy Limited (NASDAQ: BROG), and Cassava Sciences, Inc. (NASDAQ: SAVA)....

Feb 09, 2024 02:20 pm ET

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Feb 09, 2024 10:15 am ET

CASSAVA SCIENCES SHAREHOLDER ACTION REMINDER

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences To Contact Him Directly To Discuss Their Options

Feb 08, 2024 08:45 pm ET

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

NEW YORK, Feb. 8, 2024 /PRNewswire/ --

Feb 08, 2024 11:02 am ET

CASSAVA DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Thei

Feb 07, 2024 02:30 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against C ("Cassava" or the "Company") (NASDAQ: SAVA). The class action, filed in the United States District Court for the Northern District of Illinois, and docketed under 24 -cv- 00977, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between August 18, 2022 and October 12, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal

Feb 07, 2024 09:08 am ET

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the proposed treatment of Alzheimer’s disease dementia. The study...

Feb 06, 2024 11:14 am ET

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. (SAVA)

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois on behalf of all persons or entities who purchased or otherwise acquired Cassava...

Feb 05, 2024 09:51 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Feb 05, 2024 09:00 pm ET

Cassava ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) in the United States District Court...

Feb 05, 2024 04:39 pm ET

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and October 12, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 2, 2024.

Feb 05, 2024 02:35 pm ET

Cassava Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

A class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover...

Feb 05, 2024 12:53 pm ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Feb. 5, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) and certain of its officers.

Feb 05, 2024 11:24 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Feb 05, 2024 11:10 am ET

Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA) on Behalf of Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to

Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA). The lawsuit alleges Defendants made materially false and misleading statements...

Feb 05, 2024 10:55 am ET

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Jan 05, 2024 09:12 am ET

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the “Warrants”) to its shareholders. The Warrants now trade on Nasdaq under the ticker...

Dec 21, 2023 08:31 am ET

Thinking about trading options or stock in Cassava Sciences, Broadcom, Novo Nordisk, Walgreens Boots Alliance, or Calliditas Therapeutics?

NEW YORK, Dec. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, AVGO, NVO, WBA, and CALT.

Dec 12, 2023 09:13 am ET

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warrants to holders of the Company's common stock as of December 22, 2023 (the “Record Date”). Shareholders will receive...

Dec 07, 2023 04:01 pm ET

Cassava Sciences Appoints Three New Members to its Board of Directors

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise...

Nov 13, 2023 06:50 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....

Nov 07, 2023 09:01 am ET

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the third quarter ended September 30, 2023. “In the third quarter, Cassava Sciences made important...

Nov 06, 2023 09:15 am ET

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia....

Nov 05, 2023 03:22 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Nov 03, 2023 06:34 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Oct 27, 2023 01:59 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Oct 25, 2023 05:33 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK, Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Oct 25, 2023 09:15 am ET

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced a potentially significant safety finding based on interim magnetic resonance imaging (MRI) brain data from Alzheimer’s patients who are enrolled in a...

Oct 19, 2023 05:07 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Oct 17, 2023 11:06 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Oct 17, 2023 01:43 pm ET

Investigation of Cassava Sciences, Inc. (SAVA) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) complied with federal securities laws. On October 12, 2023, Science reported that, following an investigation, the City University of...

Oct 17, 2023 04:00 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of the securities laws.

Oct 16, 2023 04:00 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of the securities laws.

Oct 13, 2023 11:55 pm ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of the securities laws.

Oct 13, 2023 09:31 am ET

Thinking about buying stock in Outset Medical, Tempest Therapeutics, Cassava Sciences, Rivian Automotive, or Athersys?

NEW YORK, Oct. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OM, TPST, SAVA, RIVN, and ATHX.

Oct 12, 2023 11:43 pm ET

Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today issued the following statement regarding an internal report purportedly prepared by City University of New York (CUNY). This report...

Oct 05, 2023 09:15 am ET

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech...

Oct 02, 2023 09:00 am ET

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four (804) Alzheimer’s patients are enrolled in this 12-month trial. A second...

Sep 18, 2023 09:15 am ET

Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced a positive interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease. A routine,...

Sep 11, 2023 09:10 am ET

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam. Simufilam is Cassava Sciences’ novel drug candidate...

Sep 06, 2023 09:15 am ET

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences. Event:Morgan Stanley - 21stAnnual...

Aug 03, 2023 09:07 am ET

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2023. Net loss was $26.4 million, or $0.63 per share, compared to...

Jul 07, 2023 10:06 pm ET

CASSAVA SCIENCES INVESTIGATION UPDATE BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA). Beginning in August 2021,...

Jul 05, 2023 09:15 am ET

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced top-line clinical results from its Cognition Maintenance Study (CMS). The CMS is a small proof-of-concept study designed to demonstrate the effects of drug versus...

Jun 27, 2023 09:15 am ET

New Research Shows Simufilam Suppresses Overactive mTOR

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the publication of a new paper in Frontiers in Aging, a peer-reviewed journal focused on age-related scientific research. The new paper examined the...

Jun 24, 2023 08:52 pm ET

CASSAVA SCIENCES INVESTIGATION UPDATE BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

Jun 12, 2023 09:15 am ET

New Publication Highlights Basic Science Supporting Simufilam

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced a new science publication in Drug Development Research, a peer-reviewed journal. This article reviews certain...

Jun 01, 2023 09:15 am ET

Cassava Sciences to Present at the Jefferies Global Healthcare Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City....

May 11, 2023 09:15 am ET

Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of patient dosing in a 6-month, randomized controlled trial of simufilam in over 125 patients with Alzheimer’s disease. This trial is...

May 08, 2023 09:15 am ET

New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein. Prior research has shown that FLNA is...

May 01, 2023 09:00 am ET

Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2023. Net loss was $24.3 million, or $0.58 per share, compared to...

Apr 26, 2023 09:12 am ET

Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect...

Mar 09, 2023 07:30 am ET

Thinking about buying stock in Unicycive Therapeutics, Asana, Emergent Biosolutions, Cassava Sciences, or FuelCell Energy?

NEW YORK, March 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UNCY, ASAN, EBS, SAVA, and FCEL.

Feb 28, 2023 09:15 am ET

Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2022, and provided operating updates. Simufilam is Cassava Sciences’...

Feb 08, 2023 09:15 am ET

Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia. Simufilam, an...

Jan 24, 2023 09:15 am ET

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer’s disease dementia. This was an open-label safety study with exploratory efficacy...

Dec 20, 2022 09:15 am ET

Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD

Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passing of a...

Dec 12, 2022 08:00 am ET

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Cassava Sciences, Inc. (NASDAQ: SAVA) and Encourages Long-Term SAVA Investors to Contact the Firm

Investor protection law firm Kaskela Law LLC announces that it is investigating Cassava Sciences, Inc. (“Cassava” or the Company) (NASDAQ: SAVA) on behalf of the Company’s long-term investors. On November 17, 2021, The Wall Street Journal reported...

Dec 06, 2022 09:15 am ET

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzheimer’s disease. This study was designed to evaluate long-term drug...

Nov 22, 2022 12:29 pm ET

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667...

Nov 18, 2022 01:30 pm ET

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and...

Nov 11, 2022 10:50 pm ET

CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

Nov 07, 2022 09:00 am ET

Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical...

Nov 03, 2022 09:15 am ET

Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company. The 150+ page...

Oct 28, 2022 10:50 pm ET

CASSAVA SCIENCES INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

NEW ORLEANS, Oct. 28, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA).

Oct 27, 2022 09:15 am ET

Cassava Sciences Announces Expansion of Leadership Team

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the expansion of its leadership team with the appointment of Christopher Cook as Senior Vice President and General Counsel. This...

Oct 14, 2022 10:50 pm ET

CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

Oct 13, 2022 09:15 am ET

Cassava Sciences Announces Initiation of an Open-label Extension Study

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study. This study is designed to provide no-cost access to simufilam, an...

Oct 07, 2022 09:31 am ET

Thinking about trading options or stock in Cassava Sciences, Exxon Mobil, Twitter, Apple, or Marathon Petroleum?

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, XOM, TWTR, AAPL, and MPC.

Sep 28, 2022 09:54 am ET

Thinking about trading options or stock in Biogen, Cassava Sciences, Tesla, Meta Platforms, or Coca-Cola?

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIIB, SAVA, TSLA, META, and KO.

Sep 26, 2022 10:55 am ET

Thinking about trading options or stock in CVS Health, Exxon Mobil, Cassava Sciences, Micron Technology, or PayPal?

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVS, XOM, SAVA, MU, and PYPL.

Sep 23, 2022 09:31 am ET

Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics?

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RUBY, NXPL, MCRB, SAVA, and TCRT.

Sep 22, 2022 11:25 am ET

Thinking about trading options or stock in Block, Cassava Sciences, Apple, Centene Corp, or General Mills?

NEW YORK, Sept. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SQ, SAVA, AAPL, CNC, and GIS.

Sep 21, 2022 10:45 am ET

Thinking about buying stock in Anavex Life Sciences, Ford, Cassava Sciences, Evaxion Biotech, or Aurora Cannabis?

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, F, SAVA, EVAX, and ACB.

Sep 08, 2022 09:15 am ET

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference,...

Aug 26, 2022 08:35 am ET

Thinking about buying stock in Cassava Sciences, Allarity Therapeutics, Nio, Roblox, or Verona Pharma?

NEW YORK, Aug. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, ALLR, NIO, RBLX, and VRNA.

Aug 21, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Cassava, U.S. Bancorp, Fulgent, and Generac and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA), U.S. Bancorp (NYSE: USB), Fulgent Genetics, Inc. (NASDAQ: FLGT), and Generac...

Aug 18, 2022 10:45 am ET

Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical?

NEW YORK, Aug. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, FCEL, SAVA, CDAK, and TEVA.

Aug 18, 2022 09:15 am ET

No Evidence of Data Manipulation in Science Publication on Simufilam

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of Prevention of Alzheimer's Disease (JPAD) that there is no convincing evidence to support...

Aug 17, 2022 08:32 am ET

Thinking about buying stock in Quoin Pharmaceuticals, Bed Bath & Beyond, Cassava Sciences, Eargo, or Blue Apron?

NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QNRX, BBBY, SAVA, EAR, and APRN.

Aug 16, 2022 08:30 am ET

Kaskela Law LLC Announces Shareholder Investigation of Cassava Sciences, Inc. (SAVA) and Encourages Long-Term SAVA Investors to Contact the Firm

Aug 15, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Mercury, Cassava, and U.S. Bancorp and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TuSimple Holdings, Inc. (NASDAQ: TSP), Mercury Systems, Inc. (NASDAQ: MRCY), Cassava Sciences, Inc. (NASDAQ: SAVA), and U.S....

Aug 12, 2022 10:50 pm ET

CASSAVA SCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA).

Aug 10, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Phathom, TuSimple, Mercury Systems, and Cassava and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), TuSimple Holdings, Inc. (NASDAQ: TSP), Mercury Systems, Inc. (NASDAQ: MRCY),...

Aug 03, 2022 09:15 am ET

Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of...

Jul 31, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Corcept, Cassava, and Hannon Armstrong and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Corcept Therapeutics, Inc. (NASDAQ: CORT), Cassava Sciences, Inc. (NASDAQ: SAVA), and Hannon...

Jul 29, 2022 10:50 pm ET

CASSAVA SCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA

NEW ORLEANS, July 29, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA).

Jul 27, 2022 01:36 pm ET

Cassava Sciences Responds to Media Reports

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, reiterated today what it had previously disclosed in 2021, that certain government agencies had requested information from the Company. The media widely reported on...

Jul 27, 2022 10:40 am ET

Thinking about buying stock in Dave, Cidara Therapeutics, Cassava Sciences, Tonix Pharmaceuticals, or Kraft Heinz?

NEW YORK, July 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAVE, CDTX, SAVA, TNXP, and KHC.

Jul 25, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Cassava, and Hannon Armstrong and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc. (NASDAQ: ENOB), Corcept Therapeutics, Inc. (NASDAQ: CORT), Cassava Sciences, Inc. (NASDAQ: SAVA),...

Jul 21, 2022 05:39 pm ET

Cassava Sciences, Inc. Investors: Company Investigated by the Portnoy Law Firm

The Portnoy Law Firm advises Cassava Sciences, Inc. (NasdaqCM: SAVA) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Cassava investors that lost money on...

Jul 20, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Cassava, Hannon Armstrong, and Nio and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA), Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NYSE: HASI), and Nio, Inc....

Jul 15, 2022 10:50 pm ET

CASSAVA SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA

Jul 10, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Cassava, Cognyte, Singularity Future, and Lightwave Logic and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA), Cognyte Software (NASDAQ: CGNT), Singularity Future Technology, Inc. (NASDAQ: SGLY),...

Jul 04, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Novartis, Unity Software, Gap, and Cassava and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS), Unity Software, Inc. (NYSE: U), Gap, Inc. (NYSE: GPS), and Cassava Sciences, Inc. (NASDAQ: SAVA)....

Jun 24, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating GoodRx, Cassava, Ebix, and the WWE and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX), Cassava Sciences, Inc. (NASDAQ: SAVA), Ebix, Inc. (NASDAQ: EBIX), and World Wrestling...

Jun 01, 2022 08:30 am ET

Thinking about buying stock in Tonix Pharmaceuticals, View, vTv Therapeutics, TherapeuticsMD, or Cassava Sciences?

NEW YORK, June 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, VIEW, VTVT, TXMD, and SAVA.

May 29, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Medallion, Corcept, RBB, and Cassava and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Medallion Financial Corp. (NASDAQ: MFIN), Corcept Therapeutics, Inc. (NASDAQ: CORT), RBB Bancorp (NASDAQ: RBB), and Cassava...

May 22, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Cassava, Dentsply Sirona, IonQ, and Singularity Future and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA), Dentsply Sirona, Inc. (NASDAQ: XRAY), IonQ, Inc. (NYSE: IONQ), and Singularity Future...

May 16, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Cassava, Dentsply Sirona, IonQ, and Singularity Future and Encourages Investors to Contact the Firm

May 11, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Verra, Cassava, Dentsply Sirona, and Axsome and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verra Mobility Corp. (NASDAQ: VRRM), Cassava Sciences, Inc. (NASDAQ: SAVA), Dentsply Sirona, Inc. (NASDAQ: XRAY), and Axsome...

May 11, 2022 08:27 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK, May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

May 11, 2022 04:52 pm ET

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), The Honest Company, Inc. (NASDAQGS: HNST), PolarityTE, Inc. (NASDAQCM: PTE), Selectquote, Inc. (NYSE: SLQT) SAVA,

Cassava Sciences, Inc. (NASDAQCM: SAVA) Lifshitz Law PLLC announces that a class action complaint was filed against Cassava alleging Defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of...

May 06, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Dentsply, Cassava, and Axsome and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dentsply Sirona, Inc. (NASDAQ: XRAY), Cassava Sciences, Inc. (NASDAQ: SAVA), and Axsome Therapeutics, Inc. (NASDAQ: AXSM)....

May 05, 2022 09:00 am ET

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical...

May 03, 2022 02:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK, May 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

May 01, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Netflix, Apyx, Cassava, and Dentsply and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Netflix, Inc. (NASDAQ: NFLX), Apyx Medical Corp. (NASDAQ: APYX), Cassava Sciences, Inc. (NASDAQ: SAVA), and Dentsply Sirona...

Apr 28, 2022 02:26 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Apr 25, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Apyx, Cassava, and Dentsply Sirona and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Apyx Medical Corp. (NASDAQ: APYX), Cassava Sciences, Inc. (NASDAQ: SAVA), and Dentsply Sirona, Inc. (NASDAQ: XRAY). Our...

Apr 25, 2022 09:00 am ET

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place...

Apr 23, 2022 03:39 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK, April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Apr 22, 2022 09:00 pm ET

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm

Apr 21, 2022 09:00 pm ET

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava stockholders. Our investigation concerns whether Cassava has violated the federal securities laws and/or engaged in other unlawful business practices.

Apr 19, 2022 09:36 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Apr 19, 2022 11:05 am ET

Thinking about buying stock in Toughbuilt Industries, Camber Energy, Hallador Energy, Brickell Biotech, or Cassava Sciences?

NEW YORK, April 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, CEI, HNRG, BBI, and SAVA.

Apr 13, 2022 03:28 pm ET

Lifshitz Law Firm, P.C. Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), Coinbase Global, Inc. (NASDAQGS: COIN), HyreCar, Inc. (NASDAQCM: HYRE), and Longeveron Inc. (NASDAQCM: LGVN

Apr 04, 2022 09:00 am ET

Webcast Details for Cassava Sciences’ Upcoming Fireside Chat

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO...

Mar 30, 2022 09:00 am ET

Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and...

Feb 28, 2022 04:03 pm ET

Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates. “In second half 2021,...

Feb 11, 2022 07:30 am ET

Thinking about buying stock in Castor Maritime, Itau Unibanco, Bloom Energy, Cassava Sciences, or Leap Therapeutics?

NEW YORK, Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTRM, ITUB, BE, SAVA, and LPTX.

Feb 10, 2022 04:07 pm ET

FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by an attorney...

Dec 23, 2021 12:43 pm ET

Lifshitz Law Firm, P.C. Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), HyreCar, Inc. (NASDAQCM: HYRE), loanDepot, Inc. (NYSE LDI), and Longeveron Inc. (NASDAQCM: LGVN)

Cassava Sciences, Inc. (NASDAQCM: SAVA) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against Cassava alleging Defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity...

Dec 23, 2021 09:00 am ET

Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc., (NASDAQ: SAVA) a biotechnology company, today announced the launch of a new clinical website, called www.Rethink-ALZ.com. Rethink-ALZ.com is intended to provide access, visibility and information on Cassava Sciences’ Phase 3...

Dec 21, 2021 09:30 am ET

Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication

Cassava Sciences, Inc., (Nasdaq: SAVA) a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation in a 2005 paper1 authored by the Company and its scientific collaborators....

Dec 21, 2021 08:31 am ET

Thinking about buying stock in Quoin Pharmaceuticals, Aridis Pharmaceuticals, Biofrontera, Cassava Sciences, or Embraer SA?

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QNRX, ARDS, BFRI, SAVA, and ERJ.

Dec 04, 2021 01:56 pm ET

CORRECTING and REPLACING CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Second paragraph of release dated December 3, 2021, should read: The lawsuit alleges that... (instead of The complaint, filed on January 5, 2021, alleges that...)

Dec 03, 2021 09:00 pm ET

CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA) on behalf of long-term stockholders following a class action complaint that was filed against Cassava Sciences on August 27, 2021. Our investigation concerns whether the board of directors of Cassava Sciences have breached their fiduciary duties to the company.

Nov 18, 2021 09:15 am ET

Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease. This second Phase 3 study is designed to...

Nov 17, 2021 04:40 pm ET

CASSAVA SCIENCES INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Cassava Sciences Inc.

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Cassava Sciences Inc. (NASDAQ: SAVA) (“Cassava” or the “Company”) for potential violations of federal securities laws. If you purchased shares of Cassava Sciences Inc. and suffered losses,...

You are here

Cassava Sciences Inc (OQ:SAVA)

Business Focus: Bio Therapeutic Drugs